For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Not yet recruiting
Sat, 04/30/2016 to Thu, 04/01/2021
Bone Marrow Disease(s):
- myelodysplastic syndromes (MDS)
Drug: Fludarabine Induction and Consolidation Phase Dose of Fludarabine: 30 mg/m2 by vein over 2 hours for 4 days. Other Names: Fludarabine Phosphate Fludara Drug: Cytarabine Induction and Consolidation Phase Dose of Cytarabine: 1.5 gram/m2 continuous infusion daily for 4 days. Other Names: Ara-C Cytosar DepoCyt Cytosine Arabinosine Hydrochloride Drug: LY2606368 Induction Phase Starting Dose of LY2606368: 30 mg/m2 by vein daily for 3 days (days 1, 3, 4). Consolidation Phase Starting Dose of LY2606368: Maximum tolerated dose (MTD) from Induction Phase.